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CHARACTERIZATION OF IMMUNE CELL DISTRIBUTIONS IN MOUSE 
MODELS OF SPONTANEOUS BREAST TUMORS 
 
GLORIA SEOYOUNG PARK 
 
ABSTRACT 
 As immunotherapy grows in popularity as a cancer treatment option, we need to 
further understand how immune cells interact with the tumor microenvironment and 
influence tumor progression.  The goal of this thesis was to characterize the different 
immune, cellular, and structural components within the breast tumor tissues of two 
orthotopic (MCaP0008 and M3C) and one spontaneous (MMTV-PyVT) murine models 
of immunogenic breast cancer.  Identification of the tumor components in question, 
including CD3+ lymphocytes, CD11b+ myeloid cells, CD31+ endothelial cells, αSMA+ 
cancer associated fibroblasts, Ki67+ cells, cleaved caspase-3+ cells, collagen-1, and 
hyaluronan, were done by immunohistochemistry (IHC)-immunofluorescence (IF) 
staining of frozen tumor tissues with appropriate antibodies and imaging with 
multispectral confocal microscopy.  Quantification and further data analysis were 
performed using a custom MATLAB program designed by Dr. Mei Rosa Ng.  Gaining 
understanding of these stromal compositions will allow for better utilization of these 
breast cancer mouse models in future experiments.   
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INTRODUCTION 
  
Breast cancer is currently the second most common cause of cancer-induced death 
among women, affecting one out of eight women during her lifetime (1).  In 2015, 
approximately 231,840 new cases of invasive breast cancer will be diagnosed in women 
in the U.S., while taking the lives of about 40,290 women (1).  Some of the common 
treatments for breast cancer include mastectomy, chemotherapy, radiation therapy, 
hormonal therapy, and immunotherapy (2).  Often, appropriate and effective treatments 
involve combining some of these aforementioned modalities (2).  With the recent 
recognition of immune evasion and inflammation as hallmarks of cancer growth, many 
research efforts have turned to immunotherapy, which reinforces a patient’s immune 
system to combat cancer cells with agents such as antibodies or lymphocytes (3,4).  This 
approach focuses on triggering cancer-specific immune response and has lead to 
therapeutics such as tumor antigen vaccines and checkpoint blockade (3).  
Despite some success in achieving clinical benefits in treating solid tumors such 
as melanoma, prostate cancer, and lung cancer, many of the mechanisms behind current 
therapeutic agents require further understanding of the tumor microenvironment and 
immunosuppression in order to improve drug efficacy (3).  For instance, following the 
discovery of cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and the 
programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) 
receptor/ligand pair (immunological checkpoints that prevent immune response by 
inhibiting T cell activation), monoclonal antibodies were designed to block these immune 
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checkpoints and enable natural immune responses against tumors (5).  Specifically, these 
antagonists were expected to mobilize T lymphocytes, and recent studies have found that 
they strengthened anti-tumor immune function in patients with pancreatic ductal 
adenocarcinoma (PDAC), one of the deadliest cancers (6, 7).  However, many patients 
did not respond to these immunotherapeutic antibodies, perhaps due to other interactions 
between tumor cells and stromal cells in their tumor microenvironment.  According to a 
recent study by Feig et al., carcinoma-associated fibroblasts (CAFs) that express 
fibroblast activation protein (FAP) in tumors were suppressing the anti-tumor effects of 
the immune cells present as well as the checkpoint blockade antibodies themselves (5).  
These FAP+ stromal cells contribute to local immunosuppression by excluding T cells in 
tumor regions of cancer cells and producing a specific molecule called chemokine (C-X-
C motif) ligand 12 (CXCL12) (5).  CXCL12 contributes to impeding the active 
immunity, as the anti-tumor effect of the immune checkpoint blockade antibodies was 
observed when an inhibitor of the chemokine, AMD3100, was administered (5).  This 
example illustrates the importance of understanding the human immune system as well as 
the tumor microenvironment, since drugs cannot exert their anti-tumor effect against 
systematic manipulations by the cancerous niche.  
As increasing evidence demonstrates that breast cancers disrupt local immune 
function by suppressing both innate and adaptive immunity and causing tumorigenic 
inflammation, understanding the human immune system and tumor microenvironment is 
crucial to gaining a deeper insight on cancer and its characterization (3).  
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The Innate and Adaptive Immunity 
The human immune system has multiple mechanisms for managing different 
pathogens that enter the body.  The first line of defense consists of the outer skin and 
other epithelial surfaces, such as mucous membranes in the lining of the lung and gut (8). 
Mucous membranes also contain antimicrobial peptides called defensins, which are 
positively charged peptides that consist of 12-50 amino acids and hydrophobic domains 
in their structure (8).  While these components act as a physical barrier and help prevent 
pathogens from entering the internal system, other mechanisms are established to destroy 
those that breach the first line of defense (8).   
The innate immune system is nonspecific and quickly responds to pathogens in 
the body by utilizing complement proteins and phagocytes such as macrophages and 
neutrophils (8).  These components of early immune response are able to recognize 
specific molecular structures (pathogen-associated immunostimulants) that are commonly 
featured on many pathogens, but they are exclusive to the host and respond by 
inflammation and phagocytosis (8).  For example, the innate immune system recognizes 
formylmethionine-containing peptides at the N-terminus, since they are uniquely of 
bacterial origin, and attracts neutrophils to phagocytose the bacteria and digest with 
chemical substances such as lysozyme and acid hydrolases (8).  Once phagocytes break 
down constituent proteins of the engulfed pathogens, they attach some of the digested 
proteins on membrane glycoproteins (class II major histocompatibility complex or MHC 
class II) located on their cell surface (8).  Phagocytes displaying components of the 
digested pathogen are also called antigen-presenting cells (APCs), which trigger the 
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adaptive immune system (8).  APCs also coordinate with other subdivisions of the 
immune system to deliver intricate and purposeful reactions to pathological invasions.   
In contrast to the innate immune system, the adaptive immune system is specific 
and long-lasting, as APCs such as dendritic cells trigger humoral and cell-mediated 
immune responses from B and T lymphocytes (9).  In the humoral response, B 
lymphocytes become activated when membrane-bound antibodies unique to each B 
lymphocyte bind to an antigen immersed in extracellular fluid and begin to proliferate 
and differentiate into memory B cells and plasma cells (10).  While memory B cells 
retain the antibodies for future invasion by the same antigen, plasma cells secrete 
antibodies specific to the activated B cells, which then coat the surface of the same 
pathogens and tag them for phagocytosis, a process called opsonization (10).  Helper T 
cells also play a crucial role to facilitate the B cell activation and usually consist of Th2 
class of CD4+ T cells as well as a subset of Th1 cells (10).    
Cell-mediated immune response addresses pathogens that have infiltrated the cells 
and therefore are harder to detect in the extracellular fluid, such as a virus (10).  T 
lymphocytes can be mainly divided into helper T cells and cytotoxic T cells, the former 
of which recognizes the MHC class II containing the antigen on the surface of APCs (10).  
Each helper T cell does so via its genetically unique receptors that bind to the receptor of 
an APC, proliferating and differentiating into memory helper T cells and effector helper 
T cells (10).  Effector helper T cells release cytokines and other substances that alert the 
immune system to prepare to fight the infection and amplify the immune response (10).  
Furthermore, activated helper T cells promote humoral response by binding to MHC 
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class II on the B cell to promote B cell proliferation and differentiation (10).  This two-
fold activation of B lymphocytes exists to prevent hyperactivity of immune response and 
potential autoimmune response against self-cells (10).   
On the other hand, cytotoxic T cells typically bind to class I major 
histocompatibility complex (MHC class I), molecules which are present on the surface of 
all nucleated cells (10).  Unlike presenting digested pathogens on membrane 
glycoproteins called MHC class II in the case of APCs, the MHC class I molecules reflect 
internal activities of the cell, such as showcasing parts of the proteins being produced 
(10).  If a cell becomes infected by a virus or is cancerous, its gene expression or protein 
production is likely to be disrupted and altered, leading to foreign protein fragments on 
its MHC class I molecules (10).  These antigens on MHC class I bind to genetically 
unique receptors of cytotoxic T cells and activate them, prompting them to proliferate and 
differentiate into memory and effector cytotoxic T cells (10).  Similar to other types of 
lymphocytes, memory cytotoxic T cells exist to counter future antigens of the same type, 
and effector cytotoxic T cells kill infected and cancerous cells by releasing granzymes to 
initiate cell death and perforins to create holes in the cell membranes (10).  
As these major immune cells protect the body from infection and abnormal 
activity, understanding their molecular mechanisms and interactions is essential for 
developing effective immunotherapy.  For purposes of research, the Human Leukocyte 
Differentiation Antigens (HLDA) workshop developed a nomenclature using cluster of 
differentiation (CD) markers, which are specific structures found on the cell surface and 
are used to identify and characterize leukocytes (11).  This method of quantification and 
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qualification of lymphocytes and other types of cells serves to standardize monoclonal 
antibodies to human antigens across laboratories (11).  The CD nomenclature was 
primarily applied to human antigens but now extends to corresponding mouse antigens as 
well as antigens from other species, although only human antibodies are tested by HLDA 
(11).  CD markers are indispensable in research for recognizing specific cells in question 
and expanding our current knowledge of disease.  For instance, in both humans and mice, 
CD3, CD4, and CD8 markers are used to identify T lymphocytes (11).  More specifically, 
CD3 plays a role in T-cell receptor signal transduction (11).  CD4 is associated with 
MHC class II or helper T cells, and CD8 is related to MHC class I or cytotoxic T cells 
(11).  In addition, CD11b and CD31 identify myeloid cells and endothelial cells in mice, 
respectively (11).  These markers can be tagged with monoclonal antibodies for various 
applications such as immunohistochemistry and immunofluorescence.  As the utility of 
antibodies has grown in popularity due to their specificity, immunogenicity, and 
versatility, they can be manufactured to bind to other cells and proteins, such as 
hyaluronan, collagen, and fibroblasts, without relying on CD markers.   
 
Immunosuppression 
 While many lymphocytes and other immune cells fight against infectious and 
cancerous cells, certain subtypes work to suppress the immune response, such as 
regulatory T cells (Tregs) (12).  Under normal conditions, these inhibitory functions act 
to prevent overstimulation of immune responses and even autoimmunity (12).  However, 
in abnormal conditions such as cancer, tumor cells lull the immune system and actively 
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corrupt their surroundings (5).  Research has revealed many of these inhibitory players 
and mechanisms that have been manipulated by cancer, creating potential targets for 
cancer therapy.  Some of the cells with known immunosuppressive function include 
Tregs, tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells 
(MDSCs).  These cells are abundant in solid tumors, indicating dysfunctional or 
inefficient immunity in response to a cancerous environment (13). 
 
Regulatory T Cells (Tregs) 
Tregs are a subtype of CD4+ T lymphocytes and are thought to regulate helper T 
cells and maintain self-tolerance, which may otherwise excessively activate other effector 
cells such as CD8+ cytotoxic T cells and macrophages (12).  As important agents of 
homeostasis, Tregs detect specific antigenic peptides that are associated with the class II 
MHC molecules using their somatically rearranged T cell receptors (TCRs) (12).  This 
recognition activates Tregs to play a suppressive role (12).  Although details of the 
inhibitory pathways have yet to be unveiled, recent research has shown that Treg 
activation is antigen-specific and that its suppressive abilities are antigen-dependent (12).  
However, Tregs are not the only subtype of CD4+ cells with a known suppressive 
function, as other subtypes such as Th1, Th2, Th17, and T follicular (Tfh) cells have 
expressed similar functions to varying degrees (12).  Among general T lymphocyte 
activation markers such as CD25, CTLA-4, GITR, LAG-3, and CD127, a transcription 
factor expressed by CD4+ T cells called Foxp3 has been considered to be the most 
reliable indicator for Treg cells (12).  
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Tumor-Associated Macrophages (TAMs) 
 Contrary to the findings that cells of the adaptive immunity such as lymphocytes 
located in tumors are associated with tumor regression, cells of the innate immunity, 
particularly macrophages, appear to mainly favor tumor progression in most cancer (8).  
This generalization stems from the observation that macrophages usually arrive at the 
neoplastic lesions before other leukocytes with potential anti-tumor function, receiving 
local cues from tumors to differentiate into tumor-favoring roles (13).   
Generally, macrophages display different functional activities to maintain 
immune homeostasis, which can be immunostimulatory or immunosuppressive (13).  
Macrophages receive local signals such as chemokines that trigger transformations into 
M1 or M2 phenotypes of rather opposite functions, a process known as macrophage 
polarization (13).  M1 macrophages are the classically activated forms and are stimulated 
by bacterial products and T helper type 1 (Th1) cytokines, such as interferon-γ (13).  
These macrophages elicit the adaptive immune response and release reactive oxygen 
species (ROS) and nitrogen intermediates by secreting inflammatory and 
immunostimulating cytokines (13).  This function works to eliminate invading pathogens 
and may trigger cytotoxic activity to transformed cells (13).  On the other hand, 
alternatively activated or M2 macrophages convert in response to an abundance of Th2 
cytokines (e.g., IL-4, IL-13) and act as scavengers of tissue debris, secrete several growth 
factors to initiate tissue repair, and in turn suppress adaptive immune responses (13).  M2 
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processes are crucial to wound healing and achieving homeostasis but are prone to favor 
tumor growth in cancer (13).   
Phenotypically, TAMs resemble M2 macrophages (13).  Tumor and stromal cells 
first secrete various chemoattractants to recruit monocytes from circulation and condition 
them to become TAMs with pro-tumoral substances such as macrophage colony-
stimulating factor (M-CSF) (13).  In fact, M-CSF production in human tumors correlates 
with poor prognosis in ovarian, breast, and endometrial cancer (13).   As the monocytes 
differentiate into TAMs, they acquire immunosuppressive and pro-tumoral properties, 
playing major roles in promoting tumor cell proliferation, increasing resistance to 
apoptotic stimuli, and contributing to tumor matrix growth (13).  Moreover, TAMs 
initiate chronic inflammation in tumors that further promotes growth of tumor cells and 
vessels (13).   
 
Myeloid-Derived Suppressor Cells (MDSCs) 
 The myeloid-derived suppressor cells (MDSCs) comprise myeloid cells that later 
differentiate into macrophages, granulocytes, dendritic cells, and myeloid cells (14).  
These cells mainly accumulate in large numbers in lymphoid tissues, possess the strong 
immunosuppressive activities of T lymphocytes, and share similar attributes and gene 
expression profiles with M2-polarized TAMs (14,15).  Moreover, there was a positive 
correlation between increasing numbers of MDSCs and the tumor burden in the 
peripheral blood of cancer patients (16).  Along with macrophages, mast cells, and 
granulocytes, MDSCs are often found in both the periphery and the center of the tumor 
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(13,15).  MDSCs can generally be identified as Gr-1+ CD11b+ cells, and although these 
markers are not specific to distinguish monocytic and granulocytic subtypes, current 
research aims to define them with different surface molecules such as HIS48 (14,16).  
These cells are considered to be one of the major proponents of tumor-associated immune 
defects and may serve as a potential therapeutic target (14).  Therefore, analyzing its 
pattern of tumor infiltration and distribution with respect to other cellular and structural 
components may provide an insight into its specific role in cancer.  
 
Apoptosis and Caspase 3 
One of the mechanisms for tumor growth is suppression of cell-induced death, or 
apoptosis (17).  By evading the necessary and appropriate response to eliminate infected, 
damaged, and other unwanted cells from the body, cancer continues to plague the 
environment with uncontrollable and excessive growth (17).  For this reason, there are 
many cytotoxic anticancer agents that induce apoptosis for tumor reduction (17).  
Different extracellular and intracellular stimuli can induce apoptosis via coordinated 
activation of a family of cysteine proteases called caspases (18).  The 14 known caspases 
can be further categorized into upstream initiator caspases (caspases-8, -9, and -10) and 
downstream executioner caspases (caspases-2, -3, -6, and -7) (18, 19).  The former group 
is activated by apoptotic signals to activate the latter group, which primarily catalyzes 
specific cleavage of multiple cell proteins and causes morphological changes in apoptosis 
(18, 19).   
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Caspase-3 is integral to both the death receptor pathway initiated by caspase-8 
and the mitochondrial pathway that involves caspase-9 (18).  Several scientific studies 
have demonstrated that caspase-3 activation is necessary for inducing apoptosis as a 
response to chemotherapeutic drugs (18).  Moreover, caspase-3 cleaves “poly (ADP-
ribose) polymerase, inhibitor of caspase-activated DNase, gelsolin, 4-GDI, and EGFR, 
causing membrane blebbing, chromatin condensation, and DNA fragmentation, which are 
the hallmark changes associated with apoptosis” (19).  Thus, dysregulation of apoptosis 
would indicate potential disease manifestation, as it has been observed that several 
established breast cancer cell lines exhibit altered caspase-3 expression (19).  According 
to research by Devarajan et al., approximately 75% of the breast tumor samples and 
morphologically normal breast parenchyma samples near the tumor lacked the caspase-3 
transcript and expression of caspase-3 protein (19).  On the other hand, the expression 
level of other caspases remained normal even though complete loss of caspase-3 was 
reported (19).  Presence of activated, or cleaved, caspase-3 in breast tumors may indicate 
anti-tumor immunity and therefore serve as a positive marker for proper immune 
function.  
  
Tumor Proliferation and Ki67 
In breast cancer, tumor-proliferative activity is associated with neoplastic 
progression and metastatic potential (20).  While there are other assays to assess 
prognosis for breast cancer patients such as measuring mitotic activity, many studies 
report better assessment by using tumor proliferation marker Ki67 (20).  Specifically, 
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Ki67 is a nuclear antigen associated with regulation of the cell cycle and is universally 
expressed in proliferating cells (21).  Expression levels of Ki67 vary throughout the cell 
cycle, during which G1 and early S phase are characterized by low expression, with 
progressive increase in expression to maximal level during mitosis (M phase) (21).  Ki67 
can be assessed by means of gene expression or immunohistochemical staining (IHC) 
(21).  Although there has yet to be a consensus regarding established guidelines to 
interpret Ki67 scores, this marker has been used to predict luminal B phenotype, a high 
risk of relapse, and likelihood of good response to neoadjuvant chemotherapy (22).  In 
addition, presence of Ki67 in tumors may point to pro-tumor activity and unregulated 
immunity.  
 
Tumor Microenvironment  
 According to the National Cancer Institute at National Institutes of Health (NIH), 
tumor environment is the “normal cells, molecules, and blood vessels that surround and 
feed a tumor cell” and influences tumor growth and migration (23).  Malignant cancer 
cells mainly arise from genetic mutations that could upregulate cell proliferation and 
evade cell death, and their further growth is fostered by stromal cells, such as CAFs, and 
recruited immune cells (24).  The resulting collaborations between the neoplastic cancer 
cells and other neighboring cell types engender continual growth of the tumor and 
eventual metastasis (24).   
The detrimental effect of the tumor microenvironment also extends to tumor-
associated blood vessels which support the tumor.  Tumor vasculature is abnormal in that 
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the blood vessels are distorted and leaky, harboring conditions conducive to tumor 
growth (25).  As tumor cells proliferate and increase in size, they compress the lymph 
vessels and contribute to greater fluid pressure and blood vessel blockage (27). The 
resultant lack of oxygen, known as hypoxia, and increased pressure obstruct the delivery 
of blood, cancer-fighting immune cells, and therapeutic drugs to the tumor site (25).  
Such impediments further prompt both malignant and normal cells to secrete pro-tumor 
proteins and factors (25).  Many of these proteins are pro-angiogenic signals that induce 
new irregular vessel formation in tumors (27).  They not only suppress the function of 
various immune cells but also diminish leukocyte-endothelial interactions and prevent 
effector immune cells from infiltrating into the tumor parenchyma (27).  One particular 
protein, vascular endothelial growth factor (VEGF), is a pro-angiogenic factor that 
contributes to the leakiness of blood vessels, accumulation of MDSCs in peripheral 
immune organs, suppression of dendritic cell maturation, promotion of Treg suppression, 
and overall systemic immunosuppression (25, 28).  Moreover, VEGF further aggravates 
the leakiness of blood and lymph vessels and increases interstitial fluid pressure (25).  In 
fact, research has shown that combining anti-VEGF therapy with immunotherapy is 
associated with prolonged overall survival for cancer patients, although this finding was 
not consistent in some types of cancer, such as breast cancer (28).  Hypoxia resulting 
from abnormal tumor vasculature can also directly suppress effector T cells, alter 
metabolic pathways in cancer cells to accumulate immunosuppressive metabolites, and 
polarize tumor-associated macrophages to M2-like phenotype to further silence the 
immune response (28).  The deleterious effect of hypoxia on cancer patients was further 
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proven by research which has demonstrated that restoring blood vessels to normal with 
inhibitors of angiogenesis was followed by increased blood flow and oxygen delivery 
through brain tumors, thereby increasing some patients’ survival time (25).  Similarly, 
increased survival in patients with colon, lung, and kidney cancer was reported upon 
receiving the antiangiogenic drug bevacizumab with chemotherapy or immunotherapy 
(25).   
 The extracellular matrix also plays a crucial role in instigating a tumor-friendly 
microenvironment.  Increasing compression and hypoxia due to the abnormal tumor 
vasculature and tumor growth induce matrix-producing cells such as CAFs to upregulate 
their activity and influence certain cancer cells to also secrete matrix components (25).  
The extracellular matrix consists primarily of protein fibers such as collagen and gel-like 
components such as hyaluronan (25).  The tumor cells and the surrounding matrix 
proliferate and compress blood and lymph vessels, inducing hypoxia and other harmful 
effects (25).  While matrix composition and overall proportion of materials may differ 
across various types of cancer, research has generally shown that desmoplastic tumors, 
which possess a high ratio of matrix and fibroblasts to cancer cells, tend to be least 
responsive to drug therapy (25).  It is crucial to note that because these stromal cells are 
integral to regulation of the tumor microenvironment via complex interactions, simply 
removing these cells would not be an effective therapy for treating tumors (26).  This 
trend may offer another insight into improving drug efficacy and delivery, with lower 
matrix density potentially correlating with improved drug response (25).  
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Lymphocyte Infiltration and Immune Contexture  
 When Moore and Foote established a relationship between tumor-infiltrating 
lymphocytes (TILs) and prognosis in breast medullary carcinoma in 1949, research 
efforts have considered lymphocyte infiltration as a potential treatment target (29).  
Assessing the phenotypes of immune cells in the tumor environment in patients with 
different types of solid tumors has revealed that a majority of tumors have infiltration of 
T cells, although their immune roles may have been affected by their environment (30).  
Many studies have reported the clinical relevance of measuring lymphocytic infiltration 
for prognosis, as in the case of early-stage colorectal cancer, of which activated CD8+ T 
cells both within the tumor and in the periphery have been implicated with significant 
positive prognosis (30).  Likewise, spontaneous T cell infiltrates in patients have similar 
positive prognostic value in breast cancer, renal cell carcinoma, melanoma, ovarian 
cancer, and gastrointestinal stromal tumors (GISTs) (30).  This new approach may offer a 
different insight than the traditional TNM stages, a system which grades based on size 
and degree of the primary tumor, adjacent lymph nodes, and metastasis.  For example, the 
majority of patients with stage I and stage II cancer that had a lack of T cell tumor 
infiltration had disease recurrence in 6 years, whereas those with stage III cancer that had 
T cell infiltration had a long disease-free survival (30, 31).  This new metric of 
characterizing the immune system is called immune contexture, which refers to the 
analysis of location, density, and functional orientation of different immune cell 
populations (30).  Locations of immune cells can be largely divided into the core (center) 
of the tumor, the invasive margin, or the adjacent tertiary lymphoid structures (TLS) (15).  
	  16 
Regional differences in the immune cell composition across tumors have led to 
interesting observations.  For instance, T cells are seen only in the periphery in liver 
metastases of colon cancer, while they are present at the core and at the invasive margin 
of tumors in colorectal cancer, non-small-cell lung cancer, melanoma, and head and neck 
cancers (15).  Depending on the types of cancer and kinds of lymphocytes present, 
interpretation of their immune contexture may also vary accordingly.  For example, in 
hepatic metastases of colorectal cancer, high infiltration of CD8+ T lymphocytes in the 
periphery predicts a better response to chemotherapy and prolonged survival (15).  On the 
other hand, according to a recent study by Chen et al., only intratumoral CD8+ cytotoxic 
T lymphocytes were associated with better survival of node-negative breast cancer (32).  
Therefore, quantification of different types of immune and structural components of 
breast tumor may lead to interpretations and patterns specific to breast cancer and its 
response to therapy.   
 
MCaP0008, M3C, and MMTV-PyVT Breast Tumor Tissues 
 As the need to contextualize the tumor microenvironment is important for 
understanding disease mechanism and progression, in this thesis we assessed the 
immune, cellular, and structural profiles of three different murine breast tumor models 
and performed comparative analyses.  The three murine breast tumor models are as 
follows: MCaP0008, M3C, and MMTV-PyVT.  MCaP0008 is a cell line derived from a 
spontaneous mammary adenocarcinoma that arose in a mouse with FVB/N (Friend virus 
B-type/ NIH) background (33).  M3C is another cell line derived from a mammary 
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adenocarcinoma that arose in a MMTV-PyVT (mouse mammary tumor virus-driven 
polyoma virus middle T oncogene) transgenic mouse (also FVB/N background) (33).  
Lastly, the MMTV-PyVT transgenic mice develop spontaneous primary breast tumors 
that metastasize to lungs, which can be analogous to certain late-stage carcinomas in 
humans (34).  For both the MCaP0008 and M3C models, orthotopic tumors implanted in 
the mammary fat pad of FVB/N mice were used for the experiments in this thesis, while 
for the MMTV-PyVT model, spontaneously arising tumors, which could be 
heterogeneous in nature, were used.   
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Specific Aims/Objectives 
The goal of the experiments presented in this thesis is to quantify, locate, and 
characterize different lymphocytes and other immune cells that reside in the breast tumor 
tissues of two orthotopic (MCaP0008 and M3C) and one spontaneous (MMTV-PyVT) 
murine models of immunogenic breast cancer.  For instance, the closer CD3+ 
lymphocytes are to blood vessels marked by CD31, the more these immune cells are in 
proximity to the blood vessels and the less likely they have made contact with the tumor 
parenchyma.  We can compare where immune cells of myeloid lineage, tagged by CD11b 
markers, are located with respect to the blood vessels in the three different tumor models.  
We hypothesized that these metrics would be different across the three tumor types.  
Similarly, we can also assess the differential distributions and densities of hyaluronan, 
collagen, and alpha smooth muscle actin (αSMA), a marker of CAFs, and gain a more 
detailed characterization of the stromal components of the three tumor models.  In the 
case of cleaved caspase-3 and Ki67, we would expect to see no overlap between the two 
markers as the former is a cell death marker and the latter is a proliferation marker.  We 
can compare where these areas of cell death and proliferation occur with respect to CD8+ 
T lymphocytes in order to assess if there may be cell death associated with the presence 
of cytotoxic T cells.  All characterizations will involve immunohistochemistry (IHC)- 
immunofluorescence (IF) staining of frozen tumor tissues with appropriate antibodies, 
visualizing the IF signals under the multispectral confocal microscope, and then 
analyzing the data using special MATLAB programs designed by Dr. Mei Rosa Ng.  The 
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results will help us better understand the stromal compositions of these three breast tumor 
mouse models prior to proceeding with future experiments.  
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METHODS 
Immunohistochemistry-Immunofluorescence  (IHC-IF) Staining of Hyaluronan, 
αSMA, and Collagen I 
Frozen tissue samples of spontaneous murine mammary carcinoma from MMTV-PyVT, 
MCaP0008, and M3C models were prepared and stored at -80°C.  Twenty-micron-thick 
frozen tissue sections were fixed in acetone for 15 minutes at -20°C.  Slides were washed 
three times for three minutes each with phosphate-buffered saline (PBS).  Slides were 
then blocked for one hour with 10% fetal bovine serum (FBS) in PBS.  Biotin-conjugated 
primary antibody against hyaluronan (HABP) was used at a concentration of 16 µg/mL 
for one hour at room temperature.  The slides were then washed three times in PBS for 
three minutes each, and incubated with secondary antibody Alexa 488-streptavidin (SA) 
for two hours at room temperature.  Following washing three times with PBS for three 
minutes each, slides were blocked with 3% bovine serum albumin (BSA) and 0.2% 
Triton X-100 in PBS for one hour at room temperature.  Slides were then incubated with 
primary anti-collagen I rabbit antibody (LF-68) at a dilution of 1:60 at 4°C overnight. 
Following washing three times with PBS for three minutes each, slides were incubated 
with secondary antibody anti-rabbit Alexa 647 at a dilution of 1:200 and primary 
antibody αSMA-Cy3 at a dilution of 1:200 at room temperature for two hours.  
Following washing three times with PBS for five minutes each, slides were mounted with 
mounting media that contains 4’, 6-diamidino-2-phenylindole (DAPI) (Invitrogen 
Prolong Gold Anti-Fade).    
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IHC-IF Staining of CD31, CD3, and CD11b 
Frozen tissue samples of spontaneous murine mammary carcinoma from MMTV-PyVT, 
MCaP0008, and M3C models were prepared and stored at -80°C.  Twenty-micron-thick 
frozen tissue sections were fixed in acetone for 15 minutes at -20°C.  Slides were further 
permeabilized by 70% ethanol for five minutes at room temperature, followed by three 
washes of PBS for five minutes each.  Slides were blocked for one hour in 5% normal 
donkey serum (NDS) and 1% BSA in PBS.  Slides were incubated with primary 
antibodies anti-CD31 (Armenian hamster, AH), anti-CD3-FITC, and anti-CD11b-APC at 
a dilution of 1:100 at 4°C overnight.  Following washing three times with PBS for five 
minutes each, slides were incubated for five hours at room temperature with anti-AH 
dy549 secondary antibody at a dilution of 1:200 and DAPI counterstain at a dilution of 
1:1000 for cell nuclei.  Following washing three times with PBS for five minutes each, 
slides were mounted in Invitrogen Prolong Gold Anti-Fade mounting media.  
Fluorescence images were taken using a multispectral confocal laser-scanning 
microscope.  
 
IHC-IF Staining of Cleaved Caspase-3, Ki67, and CD8 
Frozen tissue samples of spontaneous murine mammary carcinoma from MMTV-PyVT, 
MCaP0008, and M3C models were prepared and stored at -80°C.  Twenty-micron-thick 
frozen tissue sections were fixed in acetone for 15 minutes at -20°C.  Slides were further 
permeabilized by 70% ethanol for five minutes at room temperature, followed by three 
washes of PBS for five minutes each.  Slides were blocked for one hour in 5% NDS and 
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1% BSA in PBS.  Slides were incubated with primary antibodies anti-cleaved caspase-3 
and anti-Ki67 at a dilution of 1:250 at 4°C overnight.  Following washing three times 
with PBS for five minutes each, slides were incubated for five hours at room temperature 
with secondary antibody anti-rabbit Cy3 and anti-rat Alexa Fluor 647 at a dilution of 
1:200.  Following washing three times with PBS for five minutes each, slides were 
incubated overnight at 4°C with antibody CD8-FITC at a dilution of 1:100 and DAPI 
counterstain at a dilution of 1:1000 for cell nuclei.  After washing three times with PBS 
for five minutes each, slides were mounted in Invitrogen Prolong Gold Anti-Fade 
mounting media. 
 
Imaging  
For image analysis, five to eight random fields (one to four at tumor interior and four at 
tumor periphery) at 20x magnification were taken from each slide using an Olympus 
FV1000 confocal laser-scanning microscope with an automated stage. Images were taken 
with 5.0 µm z-steps and 512 x 512 µm pixels.  
 
Data Analysis 
After imaging the immunostained tissue samples, segmentation of cells and structures 
was performed using a program designed by Dr. Mei Rosa Ng.  In addition to quantifying 
the numbers and areas of cellular structures, the program compared average distances 
between two selected features in question.  For instance, for tumors stained with 
antibodies against CD3, CD31, and CD11b, analyses were performed for metrics such as 
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the average distance between CD3+ lymphocytes and CD31+ endothelial cells or 
CD11b+ immune cells and CD31+ endothelial cells.  Data points were selected for 
analysis only if the segmentations were appropriately performed and the tissue samples 
were imaged with minimal unspecific staining.  If values from one particular field were 
deemed unusable, only those entries were removed.  Values obtained from all fields 
within the same stained tumor tissue were averaged to represent the whole tissue without 
being outnumbered by other tissues that may have more data points.  After averaging the 
mean values of samples by tumor model and stain, statistical analyses were performed 
using a software called StatPlus.  F-tests for variance and t-tests for statistically 
significant difference were performed comparing the three different mouse tumor models 
for each parameter in question.  
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RESULTS 	  
To assess the extracellular matrix composition in the three breast tumor models 
MCaP0008, M3C, and MMTV-PyVT, we performed immunostaining for αSMA+ cells, 
collagen I, and hyaluronan (Fig. 1A-B).  Figure 1C shows statistically significant 
differences found across M3C, MCaP0008, and MMTV-PyVT mice models when 
assessing the levels of αSMA+ cells.  When comparing the average area fraction of 
αSMA+ regions, there were statistically significant differences between M3C and 
MMTV-PyVT (p=0.0009) and between MCaP0008 and MMTV-PyVT tumor models 
(p=0.0003) (Fig. 1C). The average area fraction values of αSMA for M3C, MCaP0008, 
and MMTV-PyVT models were 7.44 ± 1.28%, 10.40 ± 1.21%, and 0.74 ± 0.31%, 
respectively (Fig. 1C).  There were statistically significant differences in the average area 
fraction of collagen I between M3C and MCaP0008 (p<0.001), M3C and MMTV-PyVT 
(p=0.0255), and MCaP0008 and MMTV-PyVT (p<0.0001) mice models (Fig. 1D).  The 
average area fraction values of collagen I for M3C, MCaP0008, and MMTV-PyVT 
models were 26.07 ± 2.75%, 54.05 ± 1.32%, and 18.83 ± 1.46%, respectively (Fig. 1D).  
There were statistical differences in the area fraction of hyaluronan between M3C and 
MCaP0008 (p<0.0001), M3C and MMTV-PyVT (p=0.0068), and MCaP0008 and 
MMTV-PyVT (p=0.0003) (Fig. 1E).  The values for the average area fraction of 
hyaluronan for M3C, MCaP0008, and MMTV-PyVT models were 48.77 ± 0.98%, 58.66 
± 1.24%, and 32.07 ± 5.03%, respectively (Fig. 1E).  Lastly, the average percentages of 
αSMA+ cells out of all DAPI+ cells were statistically different between M3C and 
MCaP0008 (p=0.0012), M3C and MMTV-PyVT (p=0.0001), and MCaP0008 and 
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MMTV-PyVT (p<0.0001) tumor models (Fig. 1F).  These average percentages for M3C, 
MCaP0008, and MMTV-PyVT models were 61.30 ± 3.1%, 78.42 ± 2.98%, and 22.63 ± 
6.27%, respectively.   
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Fig. 1. Immunofluorescence images and quantification of αSMA, collagen I, and hyaluronan across M3C, 
MCaP0008, and MMTV-PyVT tumor models. Description on next page. 
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Fig. 1. Immunofluorescence images and quantification of αSMA, collagen I, and hyaluronan across M3C, 
MCaP0008, and MMTV-PyVT tumor models. (A) Representative confocal images of MCaP0008, M3C, 
and MMTV-PyVT tumors (top to bottom) stained for αSMA (green), collagen I (red), and DAPI (blue). 
Confocal images were taken by randomly selecting fields at both tumor periphery and center (four fields of 
periphery per tumor, one to four fields of center per tumor, eight to ten tumors per group). (B) 
Representative confocal images of MCaP0008, M3C, and MMTV-PyVT (top to bottom) stained for 
hyaluronan (red) and DAPI (blue). (C) Quantification of average area fraction covered by αSMA in the 
three breast tumor models. n=8-10 mice per group. (D) Quantification of average area fraction covered by 
collagen I in the three breast tumor models. n=8-10 mice per group. (E) Quantification of average area 
fraction covered by hyaluronan in the three breast tumor models. n=8-12 mice per group. (F) Quantification 
of average percentage of αSMA+ cells out of all DAPI+ cells in the three breast tumor models. n=8-10 
mice per group. Error bars indicate SEM. *p<0.05 **p<0.005  
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As for comparative analysis of the same metrics between tumor periphery and 
center, there were two statistically significant differences of area fractions of αSMA+ 
cells (p=0.0014) and collagen I (p=0.00234) in the M3C model (Fig. 2A-B).  The average 
area fraction values of αSMA+ cells for tumor periphery of M3C, MCaP0008, and 
MMTV-PyVT mice models were 19.01 ± 1.31%, 10.33 ± 1.61%, and 0.74 ± 0.24%, 
respectively (Fig. 2A).  The average area fraction values of αSMA+ cells for tumor center 
of M3C, MCaP0008, and MMTV-PyVT mice models were 9.86 ± 1.40%, 9.84 ± 1.54%, 
and 1.17 ± 0.89%, respectively (Fig. 2A).  The average area fraction values of collagen I 
for tumor periphery of M3C, MCaP0008, and MMTV-PyVT mice models were 49.01 ± 
5.27%, 54.60 ± 1.35%, and 22.70 ± 1.25%, respectively (Fig. 2B).  The average area 
fraction values of collagen I for tumor center of M3C, MCaP0008, and MMTV-PyVT 
mice models were 22.59 ± 2.93%, 54.62 ± 1.75%, and 18.75 ± 2.41%, respectively (Fig. 
2B).  The average area fraction values of hyaluronan for tumor periphery of M3C, 
MCaP0008, and MMTV-PyVT mice models were 47.89 ± 0.99%, 58.09 ± 1.05%, and 
31.75 ± 5.16%, respectively (Fig. 2C).  The average area fraction values of hyaluronan 
for tumor center of M3C, MCaP0008, and MMTV-PyVT mice models were 47.89 ± 
0.99%, 58.19 ± 1.81%, and 32.41 ± 5.00%, respectively (Fig. 2C).  The average 
percentages of αSMA+ cells out of all DAPI+ cells in the tumor periphery of M3C, 
MCaP0008, and MMTV-PyVT mice models were 64.58 ± 0.03%, 78.93 ± 3.23%, and 
28.84 ± 8.34%, respectively (Fig. 2D).  The average percentages of αSMA+ cells out of 
all DAPI+ cells in the tumor center of M3C, MCaP0008, and MMTV-PyVT mice models 
were 65.33 ± 3.87%, 75.01 ± 5.24%, and 14.61 ± 8.14%, respectively (Fig. 2D). 
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Fig. 2. Quantification of αSMA+ cells, collagen I, and hyaluronan at tumor periphery and center across 
M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Quantification of average area fraction covered by 
αSMA between tumor periphery and center in the three breast tumor models. n= 5-7 mice per group. (B) 
Quantification of average area fraction covered by collagen I between tumor periphery and center in the 
three breast tumor models. n= 5-7 mice per group. (C) Quantification of average area fraction covered by 
hyaluronan between tumor periphery and center in the three breast tumor models. n= 8-12 mice per group. 
(E) Quantification of the average percentage of αSMA+ cells out of all DAPI+ cells between tumor 
periphery and center in the three tumor models. n= 5-7 mice per group. Error bars indicate SEM. *p<0.05 
**p<0.005 
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 To characterize the proximity of immune cells with respect to blood vessels in the 
three breast tumor models MCaP0008, M3C, and MMTV-PyVT, we performed 
immunostaining for CD3+ lymphocytes and CD31+ endothelial cells (Fig. 3A).  Figure 
3B shows statistically significant differences in the average area fraction of CD3+ 
lymphocytes between M3C and MCaP0008 (p=0.0326) and between M3C and MMTV-
PyVT (p=0.0056) mice models (Fig. 3B).  The values for the average area fraction of 
CD3+ lymphocytes for M3C, MCaP0008, and MMTV-PyVT models were 8.46 ± 1.22%, 
5.08 ± 0.84%, and 3.15 ± 1.15%, respectively (Fig. 3B).  Similarly, there were 
statistically significant differences in average area fraction of CD31+ endothelial cells 
between M3C and MCaP0008 (p=0.0006) and between M3C and MMTV-PyVT 
(p=0.0041) tumor models (Fig. 3C).  The values for the average area fraction of CD31+ 
endothelial cells for M3C, MCaP0008, and MMTV-PyVT models were 7.64 ± 0.61%, 
14.29 ± 1.34%, and 12.04 ± 1.16%, respectively (Fig. 3C).  Figures 3D and E show 
statistically significant differences in both average mean and average median distances of 
CD3+ lymphocytes from CD31+ endothelial cells between M3C and MCaP0008 
(p=0.0011, 0.0023, respectively) and between M3C and MMTV-PyVT (p=0.0023, 
0.0002, respectively) tumor models.  The average mean distances of CD3+ lymphocytes 
from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models were 
23.19 ± 2.29 pixels, 11.29 ± 2.02 pixels, and 10.44 ± 2.20 pixels, respectively (Fig. 3D).  
The average median distances of CD3+ lymphocytes from CD31+ endothelial cells for 
M3C, MCaP0008, and MMTV-PyVT models were 18.7 ± 2.00 pixels, 9.02 ± 1.82 pixels, 
and 6.97 ± 1.64 pixels, respectively (Fig. 3E).  Finally, statistically significant differences 
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were found in the average percentage of CD3+ lymphocytes near CD31+ endothelial 
cells between M3C and MCaP0008 (p=0.0001) and between M3C and MMTV-PyVT 
(p=0.0007) (Fig. 3F).  The values for the average percentage of CD3+ lymphocytes near 
CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models were 52.19 ± 
3.94%, 85.47 ± 4.06%, and 82.11 ± 4.4%, respectively (Fig. 3F). When looking at the 
average percentage of CD3+ lymphocytes away from CD31+ endothelial cells, 
statistically significant differences were also found between M3C and MCaP0008 
(p=0.0001) and between M3C and MMTV-PyVT (p=0.0007) tumor groups (Fig. 3G).  
The values for the average percentage of CD3+ lymphocytes away from CD31+ 
endothelial cells for M3C, MCaP0008, and MMTV-PyVT groups were 42.81 ± 3.94%, 
14.54 ± 4.06%, and 17.89 ± 4.43%, respectively (Fig. 3G). 
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Fig. 3. Immunofluorescence images and quantification of CD3+ lymphocytes and CD31+ endothelial cells 
across M3C, MCaP0008, and MMTV-PyVT tumor models. Description on next page. 
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Fig. 3. Immunofluorescence images and quantification of CD3+ lymphocytes and CD31+ endothelial cells 
across M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Representative confocal images of 
MCaP0008, M3C, and MMTV-PyVT tumors (top to bottom) stained for CD3+ lymphocytes (green), 
CD31+ endothelial cells (red), and DAPI (blue).  Confocal images were taken by randomly selecting fields 
at both tumor periphery and center (four fields of periphery per tumor, one to four fields of center per 
tumor, eight to ten tumors per group). (B) Quantification of average area fraction covered by CD3+ 
lymphocytes in the three breast tumor models. n=9-12 mice per group. (C) Quantification of average area 
fraction covered by CD31+ endothelial cells in the three breast tumor models. n=9-12 mice per group. (D) 
Average mean distances of CD3+ lymphocytes from CD31+ endothelial cells. n=9-12 mice per group. (E) 
Average median distances of CD3+ lymphocytes from CD31+ endothelial cells. n=9-12 mice per group. 
(F) Average percentages of CD3+ lymphocytes near CD31+ endothelial cells. n=9-12 mice per group. (G) 
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Average percentages of CD3+ lymphocytes far away from CD31+ endothelial cells. n=9-12 mice per 
group. Error bars indicate SEM. *p<0.05 **p<0.005 
 
When comparing the same metrics between tumor periphery and center, there was 
no statistically significant difference for all tumor models (Fig. 4A-F).  The average area 
fraction values of CD3+ lymphocytes for tumor periphery of M3C, MCaP0008, and 
MMTV-PyVT mice models were 10.16 ± 0.91%, 4.92 ± 0.97%, and 1.08 ± 0.13%, 
respectively (Fig. 4A).  The average area fraction values of CD3+ lymphocytes for tumor 
center of M3C, MCaP0008, and MMTV-PyVT mice models were 9.64 ± 0.91%, 5.70 ± 
1.11%, and 1.72 ± 0.67%, respectively (Fig. 4A).  The average area fraction values of 
CD31+ endothelial cells for tumor periphery of M3C, MCaP0008, and MMTV-PyVT 
mice models were 7.67 ± 0.76%, 15.44 ± 1.32%, and 13.59 ± 2.08%, respectively (Fig. 
4B).  The average area fraction values of CD31+ endothelial cells for tumor center of 
M3C, MCaP0008, and MMTV-PyVT mice models were 6.09 ± 0.44%, 14.52 ± 1.52%, 
and 9.55 ± 1.16%, respectively (Fig. 4B).  The average mean distances of CD3+ 
lymphocytes from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT 
models in the tumor periphery were 25.30 ± 2.48 pixels, 8.81 ± 1.03 pixels, and 7.33 ± 
1.85 pixels, respectively (Fig. 4C).  The average mean distances of CD3+ lymphocytes 
from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models in the 
tumor center were 25.63 ± 2.49 pixels, 13.12 ± 4.28 pixels, and 6.94 ± 1.38 pixels, 
respectively (Fig. 4C).  Similarly, the average median distances of CD3+ lymphocytes 
from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models in the 
tumor periphery were 20.39 ± 2.01 pixels, 6.61 ± 0.89 pixels, and 4.68 ± 1.53 pixels, 
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respectively (Fig. 4D).  The average median distances of CD3+ lymphocytes from 
CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models in the tumor 
center were 21.82 ± 2.22 pixels, 10.76 ± 3.95 pixels, and 4.57 ± 1.23 pixels, respectively 
(Fig. 4D).  The values for the average percentage of CD3+ lymphocytes near CD31+ 
endothelial cells for M3C, MCaP0008, and MMTV-PyVT models in the tumor periphery 
were 53.45 ± 3.86%, 91.23 ± 2.56%, and 90.13 ± 6.11%, respectively (Fig. 4E).  The 
values for the average percentage of CD3+ lymphocytes near CD31+ endothelial cells for 
M3C, MCaP0008, and MMTV-PyVT models in the tumor center were 50.16 ± 3.55%, 
84.71 ± 5.03%, and 86.83 ± 4.39%, respectively (Fig. 4E).  The values for the average 
percentage of CD3+ lymphocytes away from CD31+ endothelial cells for M3C, 
MCaP0008, and MMTV-PyVT groups in the tumor periphery were 46.55 ± 3.86%, 8.77 
± 2.56%, and 9.87 ± 6.11%, respectively (Fig. 4F).  The values for the average 
percentage of CD3+ lymphocytes away from CD31+ endothelial cells for M3C, 
MCaP0008, and MMTV-PyVT groups in the tumor center were 49.84 ± 3.55%, 15.29 ± 
5.03%, and 9.87 ± 4.39%, respectively (Fig. 4F). 
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Fig. 4. Quantification of CD3+ lymphocytes and CD31+ endothelial cells at tumor periphery and center 
across M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Quantification of average area fraction 
covered by CD3+ lymphocytes for tumor periphery and center in the three breast tumor models. n=7-9 
mice per group. (B) Quantification of average area fraction covered by CD31+ endothelial cells for tumor 
periphery and center in the three breast tumor models. n=7-9 mice per group. (C) Average mean distances 
of CD3+ lymphocytes from CD31+ endothelial cells for tumor periphery and center in the three breast 
tumor models. n=7-9 mice per group. (D) Average median distances of CD3+ lymphocytes from CD31+ 
endothelial cells for tumor periphery and center in the three breast tumor models. n=7-9 mice per group. (E) 
Average percentages of CD3+ lymphocytes near CD31+ endothelial cells for tumor periphery and center in 
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the three breast tumor models. n=7-9 mice per group.  (F) Average percentages of CD3+ lymphocytes far 
away from CD31+ endothelial cells for tumor periphery and center in the three breast tumor models. n=7-9 
mice per group. Error bars indicate SEM. 
 
In characterizing the proximity of immune cells with respect to blood vessels in 
the three breast tumor models MCaP0008, M3C, and MMTV-PyVT, we performed 
immunostaining for CD11b+ immune cells and CD31+ endothelial cells (Fig. 5A).  
Quantification of CD11b+ immune cells and CD31+ endothelial cells across the three 
mice groups MCaP0008, M3C, and MMTV-PyVT showed statistically significant 
differences.  Figure 5B shows statistically significant differences in the average area 
fraction of CD11b+ immune cells between M3C and MCaP0008 (p=0.049) and between 
M3C and MMTV-PyVT (p=0.0128) tumor models (Fig. 5B).  The average area fraction 
values of CD11b+ immune cells for M3C, MCaP0008, and MMTV-PyVT models were 
0.91 ± 0.25%, 0.31 ± 0.1%, and 0.11 ± 0.02%, respectively (Fig. 5B).  Figure 5C shows 
statistically significant differences in the average area fraction of CD31+ endothelial cells 
between M3C and MCaP0008 (p=0.0001) and M3C and MMTV-PyVT (p=0.0055).  The 
average area fraction values of CD11b+ immune cells for M3C, MCaP0008, and 
MMTV-PyVT models were 6.71% ± 0.52%, 15.05% ± 1.26%, and 12.70% ± 1.73%, 
respectively (Fig. 5C).  In addition, there were statistically significant differences in both 
the average mean and the average median distances of CD11b+ immune cells from 
CD31+ endothelial cells between M3C and MCaP0008 tumor models (p=0.0001, 0.0001, 
respectively) (Fig. 5D-E).  The average mean distances of CD11b+ immune cells from 
CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models were 30.89 ± 
3.00 pixels, 11.37 ± 2.28 pixels, and 20.27 ± 4.67 pixels, respectively (Fig. 5D).  The 
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average median distances of CD11b+ immune cells from CD31+ endothelial cells for 
M3C, MCaP0008, and MMTV-PyVT models were 26.05 ± 2.51 pixels, 9.23 ± 2.15 
pixels, and 16.68 ± 5.18 pixels, respectively (Fig. 5E).  Lastly, there were statistically 
significant differences in the average percentage of CD11b+ immune cells that are near 
CD31+ endothelial cells between M3C and MCaP0008 (p=0.0016) and between M3C 
and MMTV-PyVT (p=0.0004) tumor models (Fig. 5F).  The average percentages of 
CD11b+ immune cells that are near CD31+ endothelial cells for M3C, MCaP0008, and 
MMTV-PyVT models were 44.69 ± 3.94%, 76.69 ± 7.22%, and 72.41 ± 4.74%, 
respectively (Fig. 5G).  Likewise, there were statistically significant differences in the 
average percentage of CD11b+ immune cells that are far away from CD31+ endothelial 
cells between M3C and MCaP0008 (p=0.0016) and between M3C and MMTV-PyVT 
(p=0.0004) tumor models (Fig. 5G).  The average percentages of CD11b+ immune cells 
that are far away from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT 
models were 55.31 ± 3.94%, 23.31 ± 7.22%, and 27.59 ± 4.74%, respectively (Fig. 5G).  	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Fig. 5. Immunofluorescence images and quantification of CD11b+ myeloid cells and CD31+ endothelial 
cells across M3C, MCaP0008, and MMTV-PyVT tumor models. 
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Fig. 5. Immunofluorescence images and quantification of CD11b+ myeloid cells and CD31+ endothelial 
cells across M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Representative confocal images of 
MCaP0008, M3C, and MMTV-PyVT tumors (top to bottom) stained for CD11b+ myeloid cells (green), 
CD31+ endothelial cells (red), and DAPI (blue).  Confocal images were taken by randomly selecting fields 
at both tumor periphery and center (four fields of periphery per tumor, one to four fields of center per 
tumor, nine to twelve tumors per group). (B) Quantification of average area fraction covered by CD11b+ 
immune cells in the three breast tumor models. n=9-12 mice per group. (C) Quantification of average area 
fraction covered by CD31+ endothelial cells in the three breast tumor models. n=9-12 mice per group. (D) 
Average mean distances of CD11b+ immune cells from CD31+ endothelial cells. n=9-12 mice per group. 
(E) Average median distances of CD11b+ immune cells from CD31+ endothelial cells. n=9-12 mice per 
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group. (F) Average percentages of CD11b+ immune cells near CD31+ endothelial cells. n=9-12 mice per 
group. (G) Average percentages of CD11b+ immune cells far away from CD31+ endothelial cells. n=9-12 
mice per group. Error bars indicate SEM. *p<0.05 **p<0.005 
 
When comparing the same metrics between tumor periphery and center, there was 
no statistically significant difference for all three breast tumor models (Fig. 6A-F).  The 
average area fraction values of CD11b+ immune cells for tumor periphery of M3C, 
MCaP0008, and MMTV-PyVT mice models were 1.10 ± 0.33%, 0.27 ± 0.10%, and 0.11 
± 0.02%, respectively (Fig. 6A).  The average area fraction values of CD11b+ immune 
cells for tumor center of M3C, MCaP0008, and MMTV-PyVT mice models were 0.69 ± 
0.20%, 0.36 ± 0.15%, and 0.13 ± 0.04%, respectively (Fig. 6A).  The average area 
fraction values of CD31+ endothelial cells for tumor periphery of M3C, MCaP0008, and 
MMTV-PyVT mice models were 7.15 ± 0.60%, 16.03 ± 1.38%, and 12.00 ± 1.25%, 
respectively (Fig. 6B).  The average area fraction values of CD31+ endothelial cells for 
tumor center of M3C, MCaP0008, and MMTV-PyVT mice models were 5.86 ± 0.23%, 
14.36 ± 1.38%, and 11.23 ± 1.62%, respectively (Fig. 6B).  The average mean distances 
of CD11b+ immune cells from CD31+ endothelial cells for M3C, MCaP0008, and 
MMTV-PyVT models in the tumor periphery were 32.63 ± 4.44 pixels, 8.58 ± 1.20 
pixels, and 13.71 ± 2.38 pixels, respectively (Fig. 6C).  The average mean distances of 
CD11b+ immune cells from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-
PyVT models in the tumor center were 28.28 ± 1.80 pixels, 15.21 ± 5.48 pixels, and 
22.80 ± 4.97 pixels, respectively (Fig. 6C).  The average median distances of CD11b+ 
immune cells from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT 
models in the tumor periphery were 27.07 ± 3.74 pixels, 6.22 ± 1.03 pixels, and 9.53 ± 
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2.05 pixels, respectively (Fig. 6D).  Similarly, the average median distances of CD11b+ 
immune cells from CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT 
models in the tumor center were 24.45 ± 1.84 pixels, 12.99 ± 5.33 pixels, and 17.38 ± 
5.47 pixels, respectively (Fig. 6D).  The values for the average percentage of CD11b+ 
immune cells near CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT 
models in the tumor periphery were 44.70 ± 5.20%, 86.01 ± 3.56%, and 77.72 ± 4.67%, 
respectively (Fig. 6E).  The values for the average percentage of CD11b+ immune cells 
near CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT models in the 
tumor center were 46.10 ± 2.40%, 75.57 ± 7.96%, and 63.14 ± 6.63%, respectively (Fig. 
6E).  The values for the average percentage of CD11b+ immune cells far away from 
CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT groups in the tumor 
periphery were 55.30 ± 5.20%, 13.99 ± 3.56%, and 22.28 ± 4.67%, respectively (Fig. 
6F).  The values for the average percentage of CD11b+ immune cells far away from 
CD31+ endothelial cells for M3C, MCaP0008, and MMTV-PyVT groups in the tumor 
center were 53.90 ± 2.40%, 24.43 ± 7.96%, and 36.86 ± 6.63%, respectively (Fig. 6F). 
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Fig. 6. Quantification of CD11b+ myeloid cells and CD31+ endothelial cells at tumor periphery and center 
across M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Quantification of average area fraction 
covered by CD11b+ immune cells for tumor periphery and center in the three breast tumor models. n=9-10 
mice per group. (B) Quantification of average area fraction covered by CD31+ endothelial cells for tumor 
periphery and center in the three breast tumor models. n=9-10 mice per group. (C) Average mean distances 
of CD11b+ immune cells from CD31+ endothelial cells for tumor periphery and center in the three breast 
tumor models. n=9-10 mice per group. (D) Average median distances of CD11b+ immune cells from 
CD31+ endothelial cells for tumor periphery and center in the three breast tumor models. n=9-10 mice per 
group. (E) Average percentages of CD11b+ immune cells close to CD31+ endothelial cells for tumor 
periphery and center in the three breast tumor models. n=9-10 mice per group. (F) Average percentages of 
	  44 
CD11b+ immune cells far away from CD31+ endothelial cells for tumor periphery and center in the three 
breast tumor models. n=9-10 mice per group. Error bars indicate SEM.  
 
In order to assess the distribution and association between immune cells and 
markers of cell death and proliferation in the three breast tumor models MCaP0008, 
M3C, and MMTV-PyVT, we performed immunostaining for Ki67+ cells and cleaved 
caspase-3 (Fig. 7A).  Figure 7B shows statistically significant differences in the average 
area fraction of Ki67 between M3C and MMTV-PyVT (p>0.0001) and between 
MCaP0008 and MMTV-PyVT (p=0.0131) (Fig. 7B).  The average area fraction values of 
Ki67 for M3C, MCaP0008, and MMTV-PyVT were 6.92 ± 0.88%, 5.03 ± 0.84%, and 
8.06 ± 0.69%, respectively (Fig. 7B).  Although no statistically significant differences 
were observed in the average area fraction of cleaved caspase-3, the values of cleaved 
caspase-3 area fractions in M3C, MCaP0008, and MMTV-PyVT tumors were 42.40 ± 
2.97%, 39.43 ± 2.04%, and 44.76 ± 3.91%, respectively (Fig. 7C).  There was no 
statistically significant difference in the average mean or average median distances of 
Ki67+ cells from cleaved caspase-3 observed for all tumor models (Fig. 7D-E).  The 
values of the average mean distances between Ki67+ cells and cleaved caspase-3 for 
M3C, MCaP0008, and MMTV-PyVT were 1.25 ± 0.17 pixels, 0.85 ± 0.09 pixels, and 
2.17 ± 0.95 pixels, respectively (Fig. 7D).  The values of the average median distances 
between Ki67+ cells and cleaved caspase-3 for M3C, MCaP0008, and MMTV-PyVT 
were 0.76 ± 0.16 pixels, 0.55 ± 0.10 pixels, and 1.49 ± 0.79 pixels, respectively (Fig. 7E). 	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Fig. 7. Immunofluorescence images and quantification of Ki67+ cells and cleaved caspase-3 across M3C, 
MCaP0008, and MMTV-PyVT tumor models. Description on next page. 
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Fig. 7. Immunofluorescence images and quantification of Ki67+ cells and cleaved caspase-3 across M3C, 
MCaP0008, and MMTV-PyVT tumor models. (A) Representative confocal images of MCaP0008, M3C, 
and MMTV-PyVT (top to bottom) stained for Ki67 (green), cleaved caspase-3 (red), and DAPI (blue). 
Confocal images were taken by randomly selecting fields at both tumor periphery and center (four fields of 
periphery per tumor, one to four fields of center per tumor, eight to ten tumors per group). (B) 
Quantification of average area fraction covered by Ki67 in the three breast tumor models. n=9-10 mice per 
group. (C) Quantification of average area fraction covered by cleaved caspase-3 in the three breast tumor 
models. n=9-10 mice per group. (D) Average mean distances of Ki67+ cells from cleaved caspase-3. n=9-
10 mice per group. (E) Average median distances of Ki67+ cells from cleaved caspase-3. n=9-10 mice per 
group. Error bars indicate SEM. *p<0.05 **p<0.005 
 
When comparing the same metrics between tumor periphery and center, there was 
no statistically significant difference for all three breast tumor models (Fig. 8A-D).  The 
average area fraction values of Ki67+ cells for tumor periphery of M3C, MCaP0008, and 
MMTV-PyVT mice models were 7.06 ± 0.92%, 5.67 ± 1.09%, and 7.77 ± 0.74%, 
respectively (Fig. 8A).  The average area fraction values of Ki67+ cells for tumor center 
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of M3C, MCaP0008, and MMTV-PyVT mice models were 7.05 ± 1.23%, 3.88 ± 0.75%, 
and 8.63 ± 1.14%, respectively (Fig. 8A).  The average area fraction values of cleaved 
caspase-3 for tumor periphery of M3C, MCaP0008, and MMTV-PyVT mice models 
were 41.91 ± 2.61%, 41.99 ± 2.48%, and 50.65 ± 3.35%, respectively (Fig. 8B).  The 
average area fraction values of cleaved caspase-3 for tumor center of M3C, MCaP0008, 
and MMTV-PyVT mice models were 39.86 ± 3.63%, 36.80 ± 2.14%, and 44.44 ± 5.30%, 
respectively (Fig. 8B).  The average mean distances of Ki67+ cells from cleaved caspase-
3 for M3C, MCaP0008, and MMTV-PyVT models in the tumor periphery were 1.18 ± 
0.20 pixels, 0.87 ± 0.11 pixels, and 1.49 ± 0.39 pixels, respectively (Fig. 8C).  The 
average mean distances of Ki67+ cells from cleaved caspase-3 for M3C, MCaP0008, and 
MMTV-PyVT models in the tumor center were 1.33 ± 0.28 pixels, 0.81 ± 0.06 pixels, 
and 3.07 ± 2.05 pixels, respectively (Fig. 8C).  Similarly, the average median distances of 
Ki67+ cells from cleaved caspase-3 for M3C, MCaP0008, and MMTV-PyVT models in 
the tumor periphery were 0.65 ± 0.15 pixels, 0.48 ± 0.10 pixels, and 0.99 ± 0.25 pixels, 
respectively (Fig. 8D).  The average median distances of Ki67+ cells from cleaved 
caspase-3 for M3C, MCaP0008, and MMTV-PyVT models in the tumor center were 0.90 
± 0.25 pixels, 0.65 ± 0.12 pixels, and 2.33 ± 1.78 pixels, respectively (Fig. 8D). 
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Fig 8. Quantification of Ki67+ cells and cleaved caspase-3 at tumor periphery and center across M3C, 
MCaP0008, and MMTV-PyVT tumor models. (A) Quantification of average area fraction covered by 
Ki67+ for tumor periphery and center in the three breast tumor models. n=7-10 mice per group. (B) 
Quantification of average area fraction covered by cleaved caspase-3 for tumor periphery and center in the 
three breast tumor models. n=7-10 mice per group. (C) Average mean distances of Ki67+ from cleaved 
caspase-3 for tumor periphery and center in the three breast tumor models. n=9-10 mice per group.  (D) 
Average median distances of Ki67+ from cleaved caspase-3 for tumor periphery and center in the three 
breast tumor models. n=7-10 mice per group. Error bars indicate SEM.  
 
In a similar manner to Ki67+ staining, we performed immunostaining for CD8+ 
lymphocytes and cleaved caspase-3 to assess the distribution and association between 
immune cells and cell death marker in the three breast tumor models MCaP0008, M3C, 
and MMTV-PyVT (Fig. 9A).  There were no statistically significant differences in the 
average area fraction of CD8+ T lymphocytes, the average area fraction of cleaved 
caspase-3 signals, and the average median distance between CD8+ T lymphocytes and 
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cleaved caspase-3 (Fig. 9B-C, E).  The average area fraction values of CD8+ T 
lymphocytes for M3C, MCaP0008, and MMTV-PyVT were 7.41 ± 1.60%, 9.19 ± 1.33%, 
and 3.95 ± 0.89%, respectively (Fig. 9B).  The average values of cleaved caspase-3 area 
fraction in M3C, MCaP0008, and MMTV-PyVT tumors were 43.99 ± 2.27%, 44.57 ± 
1.85%, and 38.45 ± 3.32%, respectively (Fig. 9C).  There was a statistically significant 
difference in the average mean distance of CD8+ T lymphocytes from cleaved caspase-3 
signals observed between M3C and MCaP0008 (p=0.0471) (Fig. 9D).  The values of the 
average mean distance between CD8+ T lymphocytes and cleaved caspase-3 for M3C, 
MCaP0008, and MMTV-PyVT were 1.16 ± 0.12 pixels, 0.86 ± 0.04 pixels, and 2.26 ± 
0.66 pixels, respectively (Fig. 9D).  Although there was no statistically significant 
difference in the average median distance between CD8+ T lymphocytes and cleaved 
caspase-3 signals, the values for M3C, MCaP0008, and MMTV-PyVT were 0.92 ± 0.05 
pixels, 0.78 ± 0.07 pixels, and 1.64 ± 0.47 pixels, respectively (Fig. 9E). 
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Fig. 9. Immunofluorescence images and quantification of CD8+ T lymphocytes and cleaved caspase-3 
across M3C, MCaP0008, and MMTV-PyVT tumor models. Description on next page.  
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Fig. 9. Immunofluorescence images and quantification of CD8+ T lymphocytes and cleaved caspase-3 
across M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Representative confocal images of 
MCaP0008, M3C, and MMTV-PyVT (top to bottom) stained for CD8+ lymphocytes (green), cleaved 
caspase-3 (red), and DAPI (blue). Confocal images were taken by randomly selecting fields at both tumor 
periphery and center (four fields of periphery per tumor, one to four fields of center per tumor, nine to ten 
tumors per group). (B) Quantification of average area fraction covered by CD8+ T lymphocytes in the three 
breast tumor models. n=8-9 mice per group. (C) Quantification of average area fraction covered for cleaved 
caspase-3 in the three breast tumor models. n=8-9 mice per group. (D) Average mean distances of CD8+ T 
lymphocytes from cleaved caspase-3. n=8-9 mice per group. (E) Average median distances of CD8+ T 
lymphocytes from cleaved caspase-3. n=8-9 mice per group. Error bars indicate SEM. *p<0.05 **p<0.005 
 
When comparing the same metrics between tumor periphery and center, there was 
no statistically significant difference for all three breast tumor models (Fig. 10A-D).  The 
average area fraction values of CD8+ lymphocytes for tumor periphery of M3C, 
MCaP0008, and MMTV-PyVT mice models were 7.50 ± 1.69%, 8.82 ± 1.93%, and 3.94 
± 1.54%, respectively (Fig. 10A).  The average area fraction values of CD8+ 
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lymphocytes for tumor center of M3C, MCaP0008, and MMTV-PyVT mice models were 
6.87 ± 1.54%, 7.69 ± 1.17%, and 2.73 ± 1.11%, respectively (Fig. 10A).  The average 
area fraction values of cleaved caspase-3 for tumor periphery of M3C, MCaP0008, and 
MMTV-PyVT mice models were 43.79 ± 2.88%, 46.95 ± 3.12%, and 41.57 ± 5.65%, 
respectively (Fig. 10B).  The average area fraction values of cleaved caspase-3 for tumor 
center of M3C, MCaP0008, and MMTV-PyVT mice models were 42.62 ± 3.06%, 44.42 
± 2.25%, and 38.49 ± 6.04%, respectively (Fig. 10B).  The average mean distances of 
CD8+ lymphocytes from cleaved caspase-3 for M3C, MCaP0008, and MMTV-PyVT 
models in the tumor periphery were 1.12 ± 0.14 pixels, 0.86 ± 0.05 pixels, and 2.54 ± 
1.08 pixels, respectively (Fig. 10C).  The average mean distances of CD8+ lymphocytes 
from cleaved caspase-3 for M3C, MCaP0008, and MMTV-PyVT models in the tumor 
center were 1.16 ± 0.12 pixels, 0.84 ± 0.05 pixels, and 2.40 ± 1.00 pixels, respectively 
(Fig. 10C).  The average median distances of CD8+ lymphocytes from cleaved caspase-3 
for M3C, MCaP0008, and MMTV-PyVT models in the tumor periphery were 0.93 ± 0.06 
pixels, 0.88 ± 0.08 pixels, and 1.87 ± 0.75 pixels, respectively (Fig. 10D).  The average 
median distances of CD8+ lymphocytes from cleaved caspase-3 for M3C, MCaP0008, 
and MMTV-PyVT models in the tumor center were 0.92 ± 0.08 pixels, 0.71 ± 0.15 
pixels, and 1.82 ± 0.73 pixels, respectively (Fig. 10D). 
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Fig 10. Quantification of CD8+ lymphocytes and cleaved caspase-3 at tumor periphery and center across 
M3C, MCaP0008, and MMTV-PyVT tumor models. (A) Quantification of average area fraction covered by 
CD8+ lymphocytes for tumor periphery and center in the three breast tumor models. n=5-8 mice per group. 
(B) Quantification of average area fraction covered by cleaved caspase-3 for tumor periphery and center in 
the three breast tumor models. n=5-8 mice per group. (C) Average mean distances of CD8+ lymphocytes 
from cleaved caspase-3 for tumor periphery and center in the three breast tumor models. n=5-8 mice per 
group.  (D) Average median distances of CD8+ lymphocytes from cleaved caspase-3 for tumor periphery 
and center in the three breast tumor models. n=5-8 mice per group. Error bars indicate SEM.  
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DISCUSSION 
 	   This study compared immune cell infiltration as well as distribution of structural 
components across three murine breast tumor models: orthotopic MCaP0008 tumors, 
orthotopic M3C tumors, and spontaneous MMTV-PyVT tumors.  
For tumor tissues stained with antibodies against αSMA, collagen I, and 
hyaluronan, there were statistically significant differences in the average area fraction of 
αSMA between the M3C and MMTV-PyVT tumor models and between the MCaP0008 
and MMTV-PyVT tumor models (Fig. 1C).  The remaining three metrics had statistically 
significant differences across all three models for the average area fractions of collagen I 
and hyaluronan and for the average percentages of αSMA+ cells out of total DAPI+ cells 
(Fig. 1D-F).  Due to the ubiquitous nature of these components of the extracellular matrix 
in the tumors, measuring distances between these biomarkers would be difficult and was 
not performed.  Generally, MCaP0008 tumors had the highest values in the average area 
fractions of αSMA, collagen I, and hyaluronan as well as in the average percentage of 
αSMA+ cells out of total DAPI+ cells, while MMTV-PyVT consistently scored the 
lowest values (Fig. 1C-F).  Based on the compositions of αSMA, collagen I, and 
hyaluronan, MCaP0008 had the greatest amount of extracellular matrix relative to the 
other models.  By contrast, MMTV-PyVT appeared to have the least amount of 
extracellular matrix.  Dense extracellular matrix may signify a fewer number of 
infiltrating lymphocytes and pro-tumoral activities from tumoral and stromal cells, such 
as aforementioned CAFs producing FAPs (5).  Moreover, overproduction of matrix 
materials may compress blood and lymph vessels and contribute to creating a hypoxic 
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microenvironment (5).  Lastly, there were statistically significant differences in the 
average area fractions of αSMA and collagen I between M3C tumor periphery and center 
regions (Fig. 2A-B).  Both average area fractions showed that there were greater regions 
of αSMA and collagen I in the tumor periphery than in the center (Fig. 2A-B).  However, 
more statistically significant differences in other metrics comparing the tumor periphery 
and center are necessary for studying the distributions and characterizations across 
different regions of the tumor.   
For tumor tissues stained with antibodies against CD3, CD31, and CD11b, there 
were noticeable variations in the number of cells and vessels across the three tumor 
models.  For instance, M3C had much higher average area fraction of CD3+ lymphocytes 
than the other two groups, with MMTV-PyVT having the lowest value (Fig. 3B).  On the 
other hand, MCaP0008 had the highest average area fraction of CD31+ endothelial cells, 
followed by MMTV-PyVT (Fig. 3C).  While CD3 and CD11b stained for immune cells, 
CD31 stained endothelial cells, which line blood vessels.  As for the relationships 
between CD11b+ cells and blood vessels, M3C had the highest average area fraction of 
CD11b+ cells and the lowest average area fraction of CD31+ endothelial cells, while the 
opposite was observed in MMTV-PyVT (Fig. 5B-C).  In addition, it was observed that 
MCaP0008 had on average significantly more CD31+ endothelial cells than CD3+ 
lymphocytes and CD11b+ cells (Fig. 3B-C, 5B-C).  It could be speculated that dense 
extracellular matrix components triggered abnormal vascular growth for MCaP0008.   
Opposing observations were discovered in the number of CD3+ lymphocytes 
close to and far away from blood vessels.  M3C had the lowest average percentage of 
	  56 
CD3+ immune cells near CD31+ endothelial cells and the highest average percentage 
away from CD31+ endothelial cells (Fig. 3F-G).  By contrast, MCaP0008 had the highest 
average percentage of CD3+ immune cells near CD31+ endothelial cells and the lowest 
average percentage away from CD31+ endothelial cells (Fig. 3F-G).  This finding could 
imply that the dense extracellular matrix of MCaP0008 and the pro-tumor functions of 
tumor and stromal cells are contributing to exclusion of immune cells within the tumor, 
as more immune cells are trapped close to blood vessels than in the interstitium.  On the 
other hand, M3C had the lowest average percentage of CD11b+ myeloid cells near 
CD31+ endothelial cells and the highest average percentage away from CD31+ 
endothelial cells (Fig. 5F-G).  While M3C did not have the highest or the lowest density 
of extracellular matrix overall, it could be speculated that its density was low enough to 
allow movement of CD11b+ myeloid cells from the blood vessels (Fig. 1C-E).   
Of important note are the results for distance measurements between the immune 
cells and endothelial cells.  Close proximity of CD3+ cells or CD11b+ immune cells to 
CD31+ endothelial cells implies that these immune cells have recently left the blood 
vessels and most likely have not had cell-altering interactions with the tumor cells and the 
microenvironment.  The trend for both the average mean and the average median 
distances of CD3+ and CD11b+ immune cells from CD31+ endothelial cells was the 
same, with M3C tumors having the greatest distance, followed by two similar values for 
MCaP0008 and MMTV-PyVT tumors (Fig. 3D-E, 5D-E).  This finding suggests a high 
likelihood of CD3+ lymphocytes and CD11b+ myeloid cells in the M3C tumors 
interacting with the tumor cells and the microenvironment to assume tumor-favoring 
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roles rather than immunostimulatory ones.  As for the MCaP0008 and MMTV-PyVT 
models, even though the average distances between CD3+ cells and CD31+ endothelial 
cells and between CD11b+ immune cells and CD31+ endothelial cells were roughly half 
of the values for the M3C tumor model, there was no statistically significant difference in 
the average distances between MCaP0008 and MMTV-PyVT tumors to make notable 
comparisons (Fig. 3D-E, 5D-E).  
   Finally, for the tumor tissues stained with antibodies against Ki67, cleaved 
caspase-3, and CD8, MMTV-PyVT had the highest average area fraction of Ki67, a 
proliferation marker (Fig. 7B).  No statistically significant differences were observed for 
area fractions of CD8+ lymphocytes and cleaved caspase-3, a marker for apoptosis, 
among the three tumor models (Fig. 7C, 9B-C).  Interestingly, statistically significant 
differences in the average area fraction of Ki67+ cells were observed between M3C and 
MMTV-PyVT and between MCaP0008 and MMTV-PyVT, even though MMTV-PyVT 
tumors had a smaller sample size than normal due to staining error (Fig. 7B).  
 Furthermore, there was a statistically significant difference in the average mean 
distance of CD8+ lymphocytes from cleaved caspase-3 between M3C and MCaP0008 
tumor models (Fig. 9D).  Because cleaved caspase-3 is an apoptotic marker, proximity 
between CD8+ T lymphocytes and cleaved caspase-3 may indicate anti-tumoral activities 
and immunostimulatory effects.  MCaP0008 had a smaller average mean distance 
between CD8+ lymphocytes and cleaved caspase-3 than M3C, which suggests that the 
cytotoxic activity of the CD8+ T lymphocytes in MCaP0008 may be stronger than the 
activity in M3C (Fig. 9D).  Future experiments with different metrics and greater 
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statistical power are needed to further assess the extent of the cytotoxic activity of CD8+ 
T cells and its correlation with cleaved caspase-3 signals.   
By staining nine cellular and structural components with fluorescently-labeled 
antibodies and by imaging and analyzing the images, we were able to obtain small 
snapshots of the tumor microenvironment of the three tumor models and perform 
comparative analyses.  MCaP0008 had the greatest density of extracellular components 
across the three different groups, which may indicate pro-tumoral activities such as 
overproduction of the matrix materials and impediment of lymphocyte infiltration (Fig. 
1C-F).  In addition, MCaP0008 had the highest average area fraction of CD31+ 
endothelial cells, which could point to angiogenesis due to the large amount of ECM 
triggering the secretion of growth factors (Fig. 3C, 5C).  This speculation of 
immunosuppressive environment may be further supported by the observation that the 
majority of CD3+ and CD11b+ cells were found close to blood vessels rather than 
infiltrated within the tissue, suggesting that the actual immune activity in the tumor may 
be lower than expected (Fig. 3F, 5F).  However, MCaP0008 had a lower average area 
fraction of Ki67+ cells than MMTV-PyVT (Fig. 7B).  In addition, MCaP0008 had the 
shortest average mean distance between CD8+ T lymphocytes and cleaved caspase-3 
(Fig. 9D).  These two findings may imply relatively lower levels of tumor proliferation 
and stronger cytotoxic activity of the CD8+ T lymphocytes in MCaP0008 than those in 
M3C.  MCaP0008 appears to have both immunostimulatory and immunosuppressive 
activities, and further experiments are needed to clarify these contradictory speculations.   
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M3C had the highest average area fraction of CD3+ lymphocytes compared with 
the other two groups, although the amount of ECM in the group was not the lowest (Fig. 
1C-F, 3B).  M3C also had the highest average area fraction of CD11b+ cells and the 
lowest average area fraction of CD31+ endothelial cells among the three tumor models 
(Fig. 3C, 5B-C).  Although it is uncertain whether CD11b+ cells were M1 or M2 
macrophages or myeloid-derived suppressor cells, the high density of CD3+ cells 
compared with other tumor groups suggests that the M3C tumor microenvironment could 
be immunostimulatory.  This speculation is further supported by the observation that 
there were more CD3+ lymphocytes and CD11b+ cells far from blood vessels, hinting 
active immunity rather than inactive (Fig. 3F-G, 5F-G).  However, longer distances of 
CD3+ lymphocytes and CD11b+ myeloid cells from blood vessels compared with 
MCaP0008 tumors may also signify a greater likelihood of interacting with the tumor 
cells and the microenvironment and acquiring immunosuppressive qualities.  Further 
experiments are needed to investigate the relationship between CD3+ and CD11b+ 
immune cell infiltration and their roles in the tumor microenvironment.  
MMTV-PyVT appeared to have the least amount of extracellular matrix, which 
could indicate easier access for immune cells to enter the tumor tissue (Fig. 1C-F).  
However, this group had the lowest average area fraction of CD3+ lymphocytes, 
suggesting that low CD3+ lymphocyte infiltration may be due to other unknown factors 
(Fig. 3B).  Moreover, MMTV-PyVT tumors had the lowest average area fraction of 
CD11b+ cells and the highest average area fraction of Ki67+ cells (Fig. 5B, 7B).  With 
the lowest relative amount of cells with anti-tumor activities and highest relative amount 
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of tumor proliferation signals, this group appears to favor pro-tumor activities in which, 
despite the smallest amount of ECM, lymphocyte infiltration and immune activity against 
the tumor are relatively low.  These findings suggest that the proliferating MMTV-PyVT 
tumors may not have recruited as many immune cells compared with the two other tumor 
models.  
There were some limitations of this study as well as areas for improvement. 
Firstly, the segmentation program could be tailored for each stain set to better identify 
different phenotypes of stained biomarkers.  Secondly, some parameters were inherently 
difficult to quantify, such as the boundaries between Ki67 and cleaved caspase-3 because 
the former was small in size and widely scattered in the field of view.  Since the two 
biomarkers signal cell death and cell growth, one would expect to see a clear distinction 
in the respective stains; yet this was not easily achieved with automatic segmentation.  
Therefore, analyses of the average percentages of Ki67 and CD8+ T lymphocytes that are 
near and distant from cleaved caspase-3 were not possible.  Thirdly, while this study 
aimed to examine the differential distributions of immune, cellular, and structural 
components between tumor periphery and center, it found only two statistically 
significant differences in the average area fractions of αSMA and collagen I in the M3C 
tumor model.  Increasing the number of random fields taken per tumor slide as well as 
the number of tumor samples may increase the statistical power of this study, particularly 
to distinguish notable differences between tumor periphery and center.  
Future experiments could clarify some of the contradictory observations made in 
each tumor model.  For instance, staining for monocytes and macrophages with specific 
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markers in addition to CD11b may provide a detailed profiling of their distributions in the 
tumor models.  Another stain of interest would be to identify areas of hypoxia and 
angiogenesis so that observations made from extracellular matrix components and 
CD31+ endothelial cells could be further elaborated.  Staining the tissues with markers 
unique to other immune cells, such as CD4+ cells, Tregs, and MDSCs, in addition to 
Ki67 and cleaved caspase-3, could also add interesting details to characterize the tumor 
models. 
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